Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00237237 · ClinicalTrials.gov registry record · Phase 3
Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes
A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 588
- Enrollment target
- 2
- Study locations
NCT00237237: Completed Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Novartis.
NCT00237237 is a Phase 3 study of Diabetes Mellitus, Type 2 that has completed, run by Novartis. The registered enrollment target is 588 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00237237, a Phase 3 study of Diabetes Mellitus, Type 2, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 588 participants
- Enrollment target
- 2
- Study locations
Study Summary
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long-term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of pioglitazone in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone.
Conditions Studied
Interventions
- DRUG vildagliptin
Study Locations (2)
New Jersey
- Novartis Pharmaceuticals - East Hanover
Other
- Investigative Centers - Nuremberg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 588 participants |
| Start Date | 2005-10 |
| Phase | Phase 3 |
What the finished NCT00237237 record still lists
NCT00237237 is an interventional study that assigns participants to a tested intervention. The registered 588 participants enrollment target is mid-sized for trials with a published cap, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which vildagliptin is the first listed.
NCT00237237 reports a single indexed study location in New Jersey, Other.
Frequently Asked Questions
What is clinical trial NCT00237237 about?
NCT00237237 is a clinical study titled "Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes". Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long-term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of pioglitazone in lowering overall blood glucose levels wh...
What is the current status of trial NCT00237237?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 588 participants. The study started on 2005-10.
What conditions does trial NCT00237237 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT00237237?
The interventions under investigation include: vildagliptin (DRUG).
Who is sponsoring clinical trial NCT00237237?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00237237 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00237237's enrollment target sits among peer trials
588 65th of 348 higher than 283 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06921603 · 588 participants · NA
POCUS-Guided Diuresis for Decompensated Heart Failure
- NCT06986954 · 588 participants
Beacon Tip Sizing Catheter and Slip-Cath Beacon Tip Catheter Study
- NCT01365169 · 590 participants · NA
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
- NCT03774758 · 590 participants
Biomarkers for Risk Stratification in Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia